InnovAge Holding (NASDAQ:INNV) shares are trading sharply higher premarket after the PACE healthcare provider reported fiscal fourth-quarter and full-year 2026 results showing dramaticMarginexpansion and issued strong fiscal 2027 guidance. Full-year revenue grew 15.9% to $989.7 million, while adjusted EBITDA jumped approximately 175% to $94.6 …
Intel (NASDAQ:INTC) shares are trading lower premarket, giving back a portion of Tuesday's roughly 9% rally that followed a report indicating the company plans another price hike of roughly 10% on PC and enterprise CPUs starting in October, reinforcing pricing-power momentum after prior 2026 …
Meta Platforms (NASDAQ:META) shares are surging premarket following the launch of Muse, the company's long-touted AI agent capable of autonomously sending emails, booking travel, and making purchases across apps on a person's behalf. Muse is designed to access a person's apps across categories including …
Neogen (NASDAQ:NEOG) shares are trading sharply higher in pre-market trading, extending recent gains after strong institutional buying activity and improving analyst sentiment. Neogen is a global life sciences company dedicated to protecting the world's foodSupplyand improving animal health, operating through its Food Safety and …
A NASDAQ-listed clinical-stage oncology company is trading sharply lower in pre-market trading despite announcing positive updated Phase 1 data for its lead cancer therapy, a reaction that runs counter to what would typically be viewed as encouraging news. Pyxis Oncology (NASDAQ:PYXS) reported that MICVO …
Tyra Biosciences (NASDAQ:TYRA) shares are plunging over 21% in pre-market trading, giving back recent gains that had been tied to optimism around SURF302 trial data expectations in FGFR-driven cancers. Tyra Biosciences is a clinical-stage biopharmaceutical company focused on developing next-generation precision medicines targeting fibroblast …
Dyne Therapeutics (NASDAQ:DYN) shares are pulling back sharply in pre-market trading after RBC cut its price target on the stock to $30 from $35, though the firm maintained its Outperform rating with a Speculative Risk qualifier. Dyne Therapeutics is a clinical-stage biotechnology company dedicated …
Evommune (NYSE:EVMN) shares are falling sharply in pre-market trading after the company announced topline results from its Phase 2b trial evaluating EVO756 in adults with moderate-to-severe atopic dermatitis, which did not meet its primary endpoint of percent change in Eczema Area and Severityindexscore from …
Opus Genetics (NASDAQ:IRD) shares are trading higher in pre-market trading after the company reported positive low-dose Cohort 1 data from its ongoing Phase 1/2 BIRD-1 trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases, including Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Opus …
A NASDAQ-listed outpatient mental health care provider is trading lower in pre-market trading after announcing a secondary public offering by existing stockholders. LifeStance Health Group (NASDAQ:LFST) disclosed that certain existing stockholders intend to sell 22,250,000 shares of common stock, with the selling stockholders receiving …